Get the Stockscreener App
3.22
1.53%
-0.05
After Hours:
3.21
-0.01
-0.31%
Protara Therapeutics Inc stock is traded at $3.22, with a volume of 308.21K.
It is down -1.53% in the last 24 hours and down -17.65% over the past month.
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).
See More
Previous Close:
$3.27
Open:
$3.32
24h Volume:
308.21K
Relative Volume:
0.89
Market Cap:
$130.01M
Revenue:
-
Net Income/Loss:
$-42.05M
P/E Ratio:
-1.1418
EPS:
-2.82
Net Cash Flow:
$-35.26M
1W Performance:
-4.45%
1M Performance:
-17.65%
6M Performance:
+19.70%
1Y Performance:
-0.62%
1-Day Range:
$3.17
$3.338
1-Week Range:
$3.17
$3.51
52-Week Range:
$1.595
$10.48
Protara Therapeutics Inc Stock (TARA) Company Profile
Name
Protara Therapeutics Inc
Sector
Industry
Phone
646-844-0337
Address
345 PARK AVENUE SOUTH, NEW YORK, NY
Compare TARA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TARA
Protara Therapeutics Inc
|
3.22 | 130.01M | 0 | -42.05M | -35.26M | -2.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
432.00 | 115.57B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
574.16 | 60.30B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
542.47 | 37.56B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.86 | 35.18B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
224.73 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
Protara Therapeutics Inc Stock (TARA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-16-25 | Initiated | Scotiabank | Sector Outperform |
| Mar-14-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-10-23 | Resumed | Guggenheim | Buy |
| Jun-04-21 | Initiated | H.C. Wainwright | Buy |
| Feb-17-21 | Initiated | Oppenheimer | Outperform |
| Oct-19-20 | Initiated | Cowen | Outperform |
| Jul-29-20 | Initiated | Guggenheim | Buy |
View All
Protara Therapeutics Inc Stock (TARA) Latest News
Protara Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
Protara Therapeutics, Inc. (NASDAQ:TARA) Receives Average Rating of “Buy” from Brokerages - Defense World
Protara Therapeutics Reports Q1 2025 Financial Results - TipRanks
Protara Therapeutics: Q1 Earnings Snapshot - New Haven Register
Barclays PLC Takes $492,000 Position in Protara Therapeutics, Inc. (NASDAQ:TARA) - Defense World
Protara Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
Protara Therapeutics’ TARA-002: A Promising Alternative for NMIBC with Strong Efficacy and Safety Profile - TipRanks
Protara (TARA) Strengthens Leadership with Key Appointments | TA - GuruFocus
Protara Therapeutics (TARA) Sees Positive Results in TARA-002 Trial | TARA Stock News - GuruFocus
Protara (TARA) Strengthens Leadership with Key Appointments | TARA Stock News - GuruFocus
Protara Therapeutics Q1 2025 Financial Results and Business Update - TradingView
Protara Therapeutics, Inc. SEC 10-Q Report - TradingView
Protara Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Geode Capital Management LLC Buys 9,553 Shares of Protara Therapeutics, Inc. (NASDAQ:TARA) - Defense World
Renaissance Technologies LLC Sells 194,440 Shares of Protara Therapeutics, Inc. (NASDAQ:TARA) - Defense World
Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Protara Therapeutics Expands Leadership Team: New CPO Receives 61,500 Equity Awards Amid Growth Push - Stock Titan
Stocks of Protara Therapeutics Inc (TARA) are poised to climb above their peers - Sete News
It would be worthwhile to take a closer look at Protara Therapeutics Inc (TARA) - uspostnews.com
Protara Therapeutics, Inc.'s (NASDAQ:TARA) institutional investors lost 14% last week but have benefitted from longer-term gains - simplywall.st
Protara Therapeutics, Inc. (NASDAQ:TARA) Shares Sold by LPL Financial LLC - Defense World
The Potential Rise in the Price of Protara Therapeutics Inc (TARA) following insiders activity - knoxdaily.com
Biotech Co. Achieves Remarkable Cancer Treatment Results in Trial - streetwisereports.com
Protara Therapeutics Inc Inc. (TARA) Price Performance: A Technical Analysis Perspective - investchronicle.com
Balance Sheet Breakdown: Protara Therapeutics Inc (TARA)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - DWinneX
Protara Therapeutics (NASDAQ:TARA) Given “Buy” Rating at HC Wainwright - Defense World
Protara Therapeutics stock drops following interim trial results By Investing.com - Investing.com Nigeria
Protara Therapeutics stock drops following interim trial results - Investing.com Australia
Protara Therapeutics Inc (NASDAQ: TARA)’s Potential for Significant Price Increase in the Near Future - Marketing Sentinel
Protara Therapeutics Reports Positive Phase 2 Trial Results - TipRanks
Protara Therapeutics Announces Positive Interim Results Demonstr - GuruFocus
Protara Therapeutics Shares Positive Phase 2 Interim Results Of TARA-002 In Patients With NMIBC - Nasdaq
Protara Therapeutics Announces Positive Interim Results Demonstrating Durable Responses in the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC - The Manila Times
Protara Therapeutics Reports Promising Phase 2 Results for TARA-002 in Non-Muscle Invasive Bladder Cancer - Nasdaq
Breakthrough Clinical Data: New Bladder Cancer Drug Shows Perfect Response Rate in Hard-to-Treat Patients - Stock Titan
3 Stocks To Watch For When Tariffs Subside - The Globe and Mail
Mountain Province Diamonds Announces Mailing of Meeting Materials For Annual and Special Meeting of Shareholders to Approve Additional Working Capital Facility - The Globe and Mail
Protara Therapeutics (TARA) to Release Quarterly Earnings on Thursday - Defense World
Protara Therapeutics Inc (TARA) gets rating Initiated from Scotiabank - knoxdaily.com
OTCQX Best 50 Virtual Investor Conference Agenda Announced for April 24th - The Globe and Mail
Protara Therapeutics to Host Conference Call and Webcast to Review Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC on Monday, April 28, 2025 - The Manila Times
Protara Therapeutics to Host Conference Call on Phase 2 ADVANCED-2 Trial Data for TARA-002 in Non-Muscle Invasive Bladder Cancer - Nasdaq
Protara Therapeutics to Host Conference Call and Webcast to - GlobeNewswire
Protara's Bladder Cancer Drug TARA-002 Phase 2 Trial: 12-Month Efficacy Data Reveal Coming at Major Conference - Stock Titan
60 Degrees Pharmaceuticals Inc’s latest rating changes from various analysts - knoxdaily.com
No-Brainer Buy Alert: 1 Artificial Intelligence (AI) Stock With Massive Long-Term Potential - The Globe and Mail
Examining TARA’s book value per share for the latest quarter - uspostnews.com
Philip Morris (PM) To Report Earnings Tomorrow: Here Is What To Expect - The Globe and Mail
Brokerages Set Protara Therapeutics, Inc. (NASDAQ:TARA) PT at $22.50 - Defense World
Protara Therapeutics (NASDAQ:TARA) Earns Sector Outperform Rating from Analysts at Scotiabank - Defense World
Where Will Nvidia Stock Be in 5 Years? - The Globe and Mail
Protara Therapeutics Inc Stock (TARA) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):